Target

BET proteins

1 product, 1 indication

Indications

Uveal melanoma (1 products)

1 drug

4 abstracts

Abstract

A phase 1 study of the BET inhibitor ZEN003694 in combination with the MEK1/2 inhibitor binimetinib in solid tumors with RAS pathway alterations and triple-negative breast cancer (NCI number 10449).

Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, National Cancer Institute, Rockville, MD, National Cancer Institute, Cancer Therapy Evaluation Program, Rockville, MD,

Abstract

Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.

Org: Sylvester Cancer Center, AOU Careggi, Division of Hematology and Hematologic Malignancies, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Josep Carreras Leukemia Research Institute,

Abstract

Pelabresib (CPI-0610) monotherapy in high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from MANIFEST study.

Org: University of Insubria, Varese, Italy, Hematology Unit, Department of Translational Medicine, University of Eastern Piedmont and AOU Maggiore della Carità, Novara, Italy, Department of Haematology, Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, Wales, United Kingdom, Mayo Clinic Florida, Jacksonville, FL, The Richard T. Silver, M.D. Myeloproliferative Neoplasms Center, Division of Hematology and Oncology, Cornell Medicine, New York, NY,

Abstract

Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study.

Org: Sylvester Cancer Center, Emory University School of Medicine, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Hospital Germans Trias i Pujol, Institut Català D'Oncologia,

Drug

mivebresib